NTT-DATA
NTT DATA, a global leader in IT infrastructure and services, today announced a strategic partnership with Zebra Technologies, a leader in digital solutions, to accelerate innovation in the 5G device ecosystem, laying the foundation for widespread adoption across industries.
Under this multi-year agreement, NTT DATA and Zebra Technologies will co-innovate to drive the adoption of 5G devices, which is essential for Private 5G adoption. Together, the two companies will enable intelligent asset tracking that allows for real-time monitoring and management of assets in industrial and enterprise deployments, ensuring enhanced visibility, efficiencies, and security capabilities critical to Industry 4.0 supply chain management.
One critical barrier to Private 5G adoption has been the availability of 5G devices for enterprises. This partnership will bridge this gap for connected devices in the enterprise Private 5G market, which Omdia estimates will grow 35% globally over the next four years, reaching nearly $10 billion by 2028.
Empowering the Private 5G Device Landscape
The agreement establishes Zebra Technologies as a strategic partner within NTT DATA’s Device as a Service practice, making it easier for customers to access, upgrade, and simplify 5G device lifecycle management and support.
Available globally, customers will benefit from continual modernization of device deployments and the ability to harness new connectivity solutions with a leading suite of Wi-Fi, Private LTE, and Private 5G compatible devices.
This news follows NTT DATA’s recent collaboration with Qualcomm, aimed to accelerate the evolution of the 5G device ecosystem. With enterprises accelerating digital transformation, more connectivity is needed to support Industry 4.0 applications and the adoption of AI at the edge.
By leveraging NTT DATA’s Private 5G leadership and Zebra Technologies' expertise in intelligent data integration, asset management, and frontline coordination, the two companies aim to make the low latency and high-security features of Private 5G enabled devices easily accessible to frontline workers in the automotive, manufacturing, healthcare, and logistics industries.
“In our relentless pursuit to drive Private 5G and Edge AI adoption within the enterprises, we’re thrilled to join forces with Zebra Technologies globally,” said Shahid Ahmed, Group Executive Vice President, Edge Services at NTT DATA. “This alliance underscores our dedication to empowering enterprises with transformative capabilities that propel edge and Private 5G use cases and data-driven experiences.”
“Our partnership with NTT DATA underscores our commitment to bring customers the latest innovations powered by Wi-Fi, Private LTE, and Private 5G networks,” said Julie Johnson, Senior Vice President and General Manager of Enterprise Mobile Computing at Zebra Technologies. “We’re excited to leverage the global scale of NTT DATA’s capabilities to benefit our customers and be a vital part of a growing 5G device ecosystem, ensuring businesses can thrive in today’s rapidly evolving landscape.”
Elevating Network Deployment
NTT DATA is deploying a Private 5G network throughout Hyster-Yale Group’s manufacturing operations. Hyster- Yale Group is also leveraging NTT DATA’s Device as a Service to gain visibility into assets and materials and improve communications within its facilities. This network will work with Zebra Technologies’, handheld mobile computers and tablets to track assets and materials as they enter and exit manufacturing sites, providing critical business intelligence, while also seamlessly connecting engineers, onsite teams, production lines, and materials storage locations. All of this comes together through a cost-effective deployment at scale efficiently managed through NTT DATA’s Device as a Service practice.
“Adding Zebra devices to our Store Front has allowed us to procure units through our Device as a Service program with NTT DATA, offering much more SKU customization within a standard device set,” said Pierluigi Mastroddi, Director of IT Infrastructure Services at Hyster-Yale Group.
Benefits of Device as a Services Model
NTT DATA’s Device as a Service offers customers a comprehensive turnkey solution for managing the entire device lifecycle. It provides expert planning, procurement, configuration, deployment, ongoing support, analytics, repair management, and device retirement, all under the stewardship of a trusted partner. This allows customers to use a cost-effective per-user, per-month program model to consume technology products on a pay-per-user subscription basis instead of purchasing/owning the equipment.
About NTT DATA
NTT DATA is a $30+ billion trusted global innovator of business and technology services. We serve 75% of the Fortune Global 100 and are committed to helping clients innovate, optimize, and transform for long-term success. We invest over $3.6 billion each year in R&D to help organizations and society move confidently and sustainably into the digital future. As a Global Top Employer, we have diverse experts in more than 50 countries and a robust partner ecosystem of established and start-up companies. Our services include business and technology consulting, data and artificial intelligence, industry solutions, as well as the development, implementation and management of applications, infrastructure, and connectivity. We are also one of the leading providers of digital and AI infrastructure in the world. NTT DATA is part of NTT Group and headquartered in Tokyo. Visit us at nttdata.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240625541170/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom